Literature DB >> 21407908

Comparative study of risperidone and haloperidol on clinical and psychosocial parameters in treatment of schizophrenia : a randomised open trial.

A Shrivastava1, S Gopa.   

Abstract

The study compares the efficacy of risperidone and haloperidol in patients of schizophrenia on various clinical and psychosocial parameters.In the present open, comparative study, in patients suffering from schizophrenia (DSM-IV), 50 patients each were randomly treated with risperidone and haloperidol over a period of 1 year. The clinical improvement was judged on PANSS (Positive and Negative Symptom Scale) and CGIS (Clinical Global Impression Scale). The improvement in psychosocial functioning and other areas was judged using a five point scale (0-4). Though the improvement on PANSS was comparable in both the groups except on the general psychopathology subscale, on CGIS a better improvement profile was observed in risperidone group. In the other psychosocial areas such as social functioning, productivity and education a significantly more number of patients showed improvement in risperidone group as compared to haloperidol group. In significantly less number of patients suicidality and rehospitalization was found in risperidone group as compared to haloperidol group.

Entities:  

Keywords:  Risperidone; haloperidol; quality of life; social integration

Year:  2000        PMID: 21407908      PMCID: PMC2957003     

Source DB:  PubMed          Journal:  Indian J Psychiatry        ISSN: 0019-5545            Impact factor:   1.759


  7 in total

Review 1.  Quality of life in anxiety and social phobia.

Authors:  P Bech; J Angst
Journal:  Int Clin Psychopharmacol       Date:  1996-06       Impact factor: 1.659

2.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

3.  Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis.

Authors:  J Carman; J Peuskens; A Vangeneugden
Journal:  Int Clin Psychopharmacol       Date:  1995-11       Impact factor: 1.659

4.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

Authors:  G Chouinard; B Jones; G Remington; D Bloom; D Addington; G W MacEwan; A Labelle; L Beauclair; W Arnott
Journal:  J Clin Psychopharmacol       Date:  1993-02       Impact factor: 3.153

5.  Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.

Authors:  E Cesková; J Svestka
Journal:  Pharmacopsychiatry       Date:  1993-07       Impact factor: 5.788

6.  Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.

Authors:  A Claus; J Bollen; H De Cuyper; M Eneman; M Malfroid; J Peuskens; S Heylen
Journal:  Acta Psychiatr Scand       Date:  1992-04       Impact factor: 6.392

7.  Risperidone in the treatment of schizophrenia.

Authors:  S R Marder; R C Meibach
Journal:  Am J Psychiatry       Date:  1994-06       Impact factor: 18.112

  7 in total
  8 in total

1.  Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.

Authors:  Giovanni Ostuzzi; Federico Bertolini; Federico Tedeschi; Giovanni Vita; Paolo Brambilla; Lorenzo Del Fabro; Chiara Gastaldon; Davide Papola; Marianna Purgato; Guido Nosari; Cinzia Del Giovane; Christoph U Correll; Corrado Barbui
Journal:  World Psychiatry       Date:  2022-06       Impact factor: 49.548

2.  Schizophrenia research: Indian scene in last decade.

Authors:  Ajit Avasthi; Gagandeep Singh
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

3.  Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension.

Authors:  Amresh Shrivastava; Megan E Johnston; Nilesh Shah; Marco Innamorati; Larry Stitt; Meghana Thakar; David Lester; Maurizio Pompili
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

4.  Predictors of long-term outcome of first-episode schizophrenia: A ten-year follow-up study.

Authors:  Amresh Shrivastava; Nilesh Shah; Megan Johnston; Larry Stitt; Meghana Thakar
Journal:  Indian J Psychiatry       Date:  2010-10       Impact factor: 1.759

5.  An overview of Indian research in schizophrenia.

Authors:  Parmanand Kulhara; Ruchita Shah; K R Aarya
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

6.  Research on antipsychotics in India.

Authors:  Ajit Avasthi; Munish Aggarwal; Sandeep Grover; Mohd Khalid Rasheed Khan
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

7.  Research on antidepressants in India.

Authors:  Ajit Avasthi; Sandeep Grover; Munish Aggarwal
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

8.  Antipsychotic Trials in Schizophrenia from India: A Systematic Review and Meta-analysis.

Authors:  S Grover; S Sarkar
Journal:  Indian J Pharm Sci       Date:  2015 Nov-Dec       Impact factor: 0.975

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.